{
    "name": "fluocinonide",
    "comment": "Rx",
    "other_names": [
        "Lidemol",
        "Lidex",
        "Lyderm",
        "Tiamol",
        "Topactin",
        "Topsyn",
        "Vanos"
    ],
    "classes": [
        "Corticosteroids",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/vanos-fluocinonide-topical-343519",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Excretion in milk unknown; use with caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excretion in milk unknown; use with caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug or excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Chronic topical corticosteroid therapy may interfere with growth and development in children",
                "Use high potency med for <2 wk to reduce local and systemic side effects",
                "Use low potency for chronic therapy",
                "Kaposi's sarcoma reported with prolonged corticosteroid therapy  ",
                "Avoid medium to very high potency on face, folds, groin because can increase steroid absorption",
                "Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients",
                "Conditions which augment systemic absorption include application of potent steroids, use over large surface areas, prolonged use, and addition of occlusive dressings",
                "Patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests; if HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce frequency of application, or to substitute a less potent steroid",
                "Recovery of HPA axis function is generally prompt and complete upon discontinuation of drug; infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids",
                "Prolonged use may produce atrophy of skin and subcutaneous tissues; when used on intertriginous or flexor areas, or on face, this may occur even with short-term use",
                "If possible, use lower potency for children (ie, increase BSA/kg, therefore increase systemic absorption)",
                "In presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted; if a favorable response does not occur promptly, corticosteroid should be discontinued until infection has been adequately controlled",
                "Children may exhibit greater susceptibility to corticosteroid-induced HPA axis suppression and Cushing's syndrome due to larger skin surface area to body weight ratio"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Skin atrophy",
            "percent": "2"
        },
        {
            "name": "Striae",
            "percent": null
        },
        {
            "name": "Acneform lesions",
            "percent": null
        },
        {
            "name": "Pigmentation changes",
            "percent": null
        },
        {
            "name": "HPA suppression",
            "percent": null
        },
        {
            "name": "with higher potency used",
            "percent": null
        },
        {
            "name": "wk",
            "percent": null
        },
        {
            "name": "Intracranial hypertension",
            "percent": null
        },
        {
            "name": "Hypopigmentation",
            "percent": null
        },
        {
            "name": "Maceration of the skin",
            "percent": null
        },
        {
            "name": "Miliaria",
            "percent": null
        },
        {
            "name": "Folliculitis",
            "percent": null
        },
        {
            "name": "Hyperglycemia",
            "percent": null
        },
        {
            "name": "Cushing",
            "percent": null
        },
        {
            "name": "s syndrome",
            "percent": null
        },
        {
            "name": "Telangiectasia",
            "percent": null
        },
        {
            "name": "Hyperglycemia",
            "percent": null
        },
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Irritation",
            "percent": null
        },
        {
            "name": "Glycosuria",
            "percent": null
        }
    ]
}